Patients With Advanced Nsclc clinical trials

Explore recruiting patients with advanced nsclc clinical trials.

Recruiting patients with advanced nsclc studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Patients With Advanced Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

Italy, Romania, Poland, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

MILES 5 – A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation

Spain, Italy, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)

Netherlands, Italy, France, Belgium, Germany, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A PHASE 2 STUDY OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) IN COMBINATION WITH BNT116 (FIXVAC LUNG) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 ≥50%.

Spain, Germany, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

Belgium, Netherlands, France, Spain, Germany, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Patients With Advanced Nsclc trials by city

Patients With Advanced Nsclc clinical trials

Recruiting patients with advanced nsclc studies right now

Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Also recruiting in Europe

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

MILES 5 – A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)

A PHASE 2 STUDY OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) IN COMBINATION WITH BNT116 (FIXVAC LUNG) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 ≥50%.

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

Patients With Advanced Nsclc trials by city

Other conditions